Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus

Brain Research

Volumn 1609, Issue 1, 2015, Pages 31-39

  Graef, John D ^a   Newberry, Kimberly ^a   Newton, Amy ^a   Pieschl, Rick ^a   Shields, Eric ^a   Luan, Fu Ni ^a   Simmermacher, Jean ^a   Luchetti, David ^a   Schaeffer, Eric ^a   Li, Yu Wen ^a   Kiss, Laszlo ^a   Bristow, Linda J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ex vivo; Hippocampus; Long term potentiation; NMDA receptors; NR2B subunit; Plasticity; Treatment resistant depression

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; TRAXOPRODIL; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; EXCITATORY POSTSYNAPTIC POTENTIAL SUMMATION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; TREATMENT RESISTANT DEPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ELECTROSTIMULATION; MALE; METABOLISM; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; TIME; TISSUE CULTURE TECHNIQUE;

ANIMALIA; RATTUS;

ANIMALS; ANTIDEPRESSIVE AGENTS; ELECTRIC STIMULATION; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; KETAMINE; LONG-TERM POTENTIATION; MALE; PIPERIDINES; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS; TISSUE CULTURE TECHNIQUES;

EID: 84933060078     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.03.019     Document Type: Article

References (41)

1. Allaman, I., et al., 2011. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 216 (1), 75-84.
2. Autry, A.E., et al., 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (7354), 91-95.
3. Bath, K.G., et al., 2012. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 37 (5), 1297-1304.
4. Berman, R.M., et al., 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354.
5. Bliss, T.V., Collingridge, G.L., 2013. Expression of NMDA receptor-dependent LTP in the hippocampus: bridging the divide. Mol. Brain 6, 5.
6. Browne, C.A., Lucki, I., 2013. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front. Pharmacol. 4, 161.
7. Buck, N., Cali, S., Behr, J., 2006. Enhancement of long-term potentiation at CA1-subiculum synapses in MK-801-treated rats. Neurosci. Lett. 392 (1-2), 5-9.
8. Burgdorf, J., et al., 2013. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38 (5), 729-742.
9. Chen, B., et al., 2001. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 50 (4), 260-265.
10. Duncan Jr., W.C., Zarate Jr., C.A., 2013. Ketamine, sleep, and depression: current status and new questions. Curr. Psychiatry Rep. 15 (9), 394.
11. Duncan, W.C., et al., 2013. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 16 (2), 301-311.
12. Dwivedi, Y., et al., 2003. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 60 (8), 804-815.
13. Ferrer-Montiel, A.V., et al., 1998. Selected peptides targeted to the NMDA receptor channel protect neurons from excitotoxic death. Nat. Biotechnol. 16 (3), 286-291.
14. Graef, J.D., et al., 2013. Slice XVIvo: a novel electrophysiology system with the capability for 16 independent brain slice recordings. J. Neurosci. Methods 212 (2), 228-233.
15. Grover, L.M., et al., 2009. LTP in hippocampal area CA1 is induced by burst stimulation over a broad frequency range centered around delta. Learn. Mem. 16 (1), 69-81.
16. Hansen, K.B., et al., 2014. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron 81 (5), 1084-1096.
17. Heusler, P., Tourette, A., Cussac, D., 2015. Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model. Naunyn Schmiedebergs Arch. Pharmacol.
18. Ibrahim, L., et al., 2012. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 32 (4), 551-557.
19. Kawai, M., et al., 2007. Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone - a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain. Bioorg. Med. Chem. Lett. 17 (20), 5558-5562.
20. Kohr, G., et al., 2003. Intracellular domains of NMDA receptor subtypes are determinants for long-term potentiation induction. J. Neurosci. 23 (34), 10791-10799.
21. Kossel, A.H., et al., 2001. A caged Ab reveals an immediate/instructive effect of BDNF during hippocampal synaptic potentiation. Proc. Natl. Acad. Sci. USA 98 (25), 14702-14707.
22. Li, N., et al., 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (5994), 959-964.
23. Li, N., et al., 2011. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69 (8), 754-761.
24. Liu, H.T., et al., 2001. Modulation of NMDA receptor function by ketamine and magnesium: Part I. Anesth. Analg. 92 (5), 1173-1181.
25. Lu, B., 2003. BDNF and activity-dependent synaptic modulation. Learn. Mem. 10 (2), 86-98.
26. Luo, J., et al., 1997. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol. Pharmacol. 51 (1), 79-86.
27. Maeng, S., et al., 2008. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63 (4), 349-352.
28. Messaoudi, E., et al., 2002. Brain-Derived Neurotrophic Factor Triggers Transcription-Dependent, Late Phase Long-Term Potentiation In Vivo. J. Neurosci. 22 (17), 4753-7461.
29. Moosavi, M., et al., 2012. The effect of sub-anesthetic and anesthetic ketamine on water maze memory acquisition, consolidation and retrieval. Eur. J. Pharmacol. 677 (1-3), 107-110.
30. Normann, C., et al., 2007. Long-term plasticity of visually evoked potentials in humans is altered in major depression. Biol. Psychiatry 62 (5), 373-380.
31. Preskorn, S.H., et al., 2008. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28 (6), 631-637.
32. Rauner, C., Kohr, G., 2011. Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. J. Biol. Chem. 286 (9), 7558-7566.
33. Ribeiro, P.O., et al., 2014. Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices. Brain. Res. 1560, 10-17.
34. Sheline, I., et al., 1996. Hippocampal atrophy in recurrent major depression. PNAS 93, 3908-3913.
35. Shipton, O.A., Paulsen, O., 2014. GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 369 (1633), 20130163.
36. Volianskis, A., et al., 2013. Different NMDA receptor subtypes mediate induction of long-term potentiation and two forms of short-term potentiation at CA1 synapses in rat hippocampus in vitro. J. Physiol. 591 (Pt 4), 955-972.
37. Wang, J.W., et al., 2008. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J. Neurosci. 28 (6), 1374-1384.
38. Ying, S.W., et al., 2002. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J. Neurosci. 22 (5), 1532-1540.
39. Zarate Jr., C.A., et al., 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864.
40. Zhang, X.H., et al., 2008. Induction- and conditioning-protocol dependent involvement of NR2B-containing NMDA receptors in synaptic potentiation and contextual fear memory in the hippocampal CA1 region of rats. Mol. Brain 1, 9.
41. Zhou, W., et al., 2014. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur. Psychiatry 29 (7), 419-423.